Treats Major Depressive Disorder. ANDA 75525, held by Sciegen Pharms. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 75525 (Fluoxetine Hydrochloride), held by Sciegen Pharms, was first approved by FDA on Jun 27, 2002, with 6 approved supplements and 0 published complete response letters.
Fluoxetine is indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder. Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD). Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa. Acute treatment of Panic Disorder, with or without agoraphobia. Fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 27, 2002 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluoxetine HydrochlorideEQ 20MG BASE/5ML · solution;oral | Fluoxetine Hydrochloride | Rx |
| May 5, 2025 | Supplement 7Manufacturing | Approved | None posted |
| Sep 20, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 31, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 27, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 11, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 27, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters